Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02344511
Other study ID # DUR001-304
Secondary ID
Status Withdrawn
Phase Phase 3
First received January 10, 2015
Last updated September 22, 2016
Start date March 2016
Est. completion date April 2019

Study information

Verified date September 2016
Source Durata Therapeutics Inc., an affiliate of Allergan plc
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Dalbavancin for Pediatric Osteomyelitis


Description:

A Phase 3, Multicenter, Double-Blind, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Hematogenous Osteomyelitis of the Long Bones Known or Suspected to be due to Gram-Positive Organisms.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date April 2019
Est. primary completion date October 2018
Accepts healthy volunteers No
Gender Both
Age group 2 Years to 16 Years
Eligibility Inclusion Criteria:

1. Male or female 2-16 yrs

2. diagnosis of Acute Hematogenous Osteomyelitis (AHOM) of the long bones (ulna, radius, femur, tibia) defined by the following clinical signs and symptoms (< 2 weeks in duration; multiple sites of infection within long bones):

3. Limb abnormality: Pain, point tenderness upon palpation, motion restriction, loss of function

4. Magnetic resonance imaging (MRI) -OR- Gram-positive cocci documented on a Gram-stain from a bone specimen or from blood cultures.

5. Elevated C-Reactive Protein (CRP)

6. informed consent

7. willing and able to comply with the study protocol

8. Life Expectancy with appropriate antibiotic therapy and thru study duration

Exclusion Criteria:

1. Treatment with an investigational drug within 30 days preceding the first dose of study medication.

2. Receipt of > 24 hours of potentially effective intravenous antibacterial therapy for AHOM within 96 hours before randomization, unless the pathogen isolated was documented to be Methicillin resistant Staphylococcus aureus (MRSA) that was resistant to the administered antibiotic.

3. Evidence of subacute or chronic osteomyelitis including: symptoms > 2 weeks in duration

4. AHOM of non-long bones (e.g., pelvis or spine).

5. Extraosseous findings such as: subperiosteal abscess, pyomyositis, venous thrombosis, or pulmonary embolism.

6. Previous history of septic arthritis or osteomyelitis.

7. Major trauma, open-fracture, puncture wound of the foot, post-operative osteomyelitis, foreign body in or adjacent to affected bone or joint, or other iatrogenic bone or joint infections present at the site of infection.

8. Septic arthritis that is non-contiguous to osteomyelitis

9. Immunosuppression/immune deficiency

10. Evidence of Gram-negative bacteria by gram stain in the absence of Gram-positive organisms; fungus or mycobacteria at baseline.

11. Gram-negative bacteremia, even in the presence of gram-positive infection or gram-positive bacteremia.

12. A history of oral ulcers preceding the onset of musculoskeletal findings, recent gastrointestinal surgery (within 2 months)

13. Infection due to an organism known prior to study entry to be not susceptible to dalbavancin (dalbavancin mean inhibitory concentration > 0.12 µg/mL) or vancomycin (vancomycin mean inhibitory concentration (MIC) > 2 µg/mL).

14. Concomitant systemic antibacterial therapy for Gram-positive infections (eg. Rifampin, gentamicin).

15. Concomitant condition requiring any antibiotic therapy that would interfere with the assessment of study drug for the condition under study.

16. Sickle cell anemia.

17. Cystic fibrosis.

18. hypersensitivity to glycopeptide antibiotics.

19. not expected to survive for 3 months.

20. Positive urine (or serum) pregnancy test

21. Women of Child Bearing Potential who are unwilling or unable to use adequate contraceptive precautions.

22. Other severe acute or chronic medical or psychiatric condition would make the patient inappropriate for entry into this study.

23. Unwilling or unable to follow study procedures.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Dalbavancin
Drug
cefazolin, nafcillin, oxacillin or vancomycin
Standard of Care

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Durata Therapeutics International BV (an Affiliate of Actavis, Inc.)

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients with clinical improvement at Day 8 Day 8 No
Secondary Number of clinical responders Day 8 No
Secondary Average reduction in C-reactive Protein (CRP) relative to the highest value Day 8 No
Secondary Number of clinical responders by pathogen Day 8 No
Secondary Number of Participants with Adverse Events 6 months No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04563325 - Oral-only Antibiotics for Bone and Joint Infections in Children Phase 4
Not yet recruiting NCT06402292 - Surgical Treatment of Osteoarticular Infections Using Bioactive Bone Substitute N/A
Completed NCT03846804 - Next-Generation Sequencing for Pathogen Detection and Quantification in Children With Musculoskeletal Infections N/A
Active, not recruiting NCT04945434 - Clinical Effectiveness of S53P4 Bioactive Glass in Treatment of Long-bone Chronic Osteomyelitis N/A
Recruiting NCT06084754 - Effect of Pulsed Electromagnetic Field Stimulation on Localized Pediatric Osteomyelitis N/A
Recruiting NCT05177107 - Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis Phase 2
Recruiting NCT04554108 - Acute Non-severe Osteomyelitis in Children - Outpatient Management Strategy With Oral Antibiotic Therapy Compared to a Standard Strategy With Conventional Hospitalization and Intravenous Antibiotic Therapy: a Randomized Open-label Non-inferiority Study With Bayesian and Medical-economic Analyses. N/A
Recruiting NCT02128256 - CERAMENT™|G - Bone Healing and Re-infection Prophylaxis Phase 4
Terminated NCT01612962 - Diagnostic Tests to Help Determine Osteomyelitis N/A
Terminated NCT03091439 - Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis Phase 2
Recruiting NCT04936958 - RETR(Osteomyelitis)
Completed NCT03802552 - Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections Phase 1
Completed NCT03559530 - Acinetobacter Baumannii-related Osteomyelitis: Clinical and Epidemiological Characterization
Completed NCT00324922 - Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis Phase 3
Completed NCT02084147 - PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases N/A
Terminated NCT02099240 - Patients Response to Early Switch To Oral:Osteomyelitis Study Early Phase 1
Completed NCT00402064 - The Influence of Bisphosphonates in the Oral Cavity in Children N/A
Terminated NCT02168816 - Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis Phase 2
Completed NCT02685033 - Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis Phase 2
Completed NCT02335905 - Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children Phase 1/Phase 2